Mylan and Abbott: it's still on
This article was originally published in Scrip
Mylan and Abbott have tweaked the terms of the deal under which Mylan will acquire part of Abbott's generic drugs business. The move is likely a response to the US government's adjustment of its tax laws to make "inversion" deals less attractive, and signals that the deal is going ahead. The US move, made in September (scripintelligence.com, 23 September 2014), led to the collapse of AbbVie's bid for Shire last week (scripintelligence.com, 16 October 2014).